Difference between revisions of "Hypericum-trazodone"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = trazodone  
 
| to = trazodone  
 
| stop =  
 
| stop =  
* Administration of hypericum can be stopped abruptly.
+
* '''Day 1-14:'''Gradually decrease the dosage of hypericum.
| start =  
+
* '''Day 15:''' stop administration of hypericum.
* '''Day 1-7:''' a wash-out period of one week is necessary.
+
| start =
* '''Day 8:''' start administration of trazodone in a dosage of 150 mg/day.
+
* '''Day 15-30:''' a wash-out period of at least two weeks is necessary.  
* '''Day 15:''' increase dosage of trazodone to 300 mg/day.
+
* '''Day 31:''' start trazodone 100-150 mg/day.
* If necessary, increase dosage of trazodone further.
 
 
| info =  
 
| info =  
* Occurrence of the serotonin syndrome is theoretically possible. }}
+
* Occurrence of the serotonin syndrome is possible without wash-out period.
 +
* Hypericum induces enzymes of the CYP P-450 type and P-gp.
 +
* Hypericum probably has MAO-inhibiting properties.}}

Revision as of 10:00, 15 July 2009

Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort
Trazodone
Type Antidepressant
Group other
links
Medscape Trazodone
PubChem 5533
PubMed Trazodone
Kompas (Dutch) Trazodone
Wikipedia Trazodone

Switch medication from hypericum to trazodone.[1] [2]

Nietinrijdenbord.png Stop hypericum
  • Day 1-14:Gradually decrease the dosage of hypericum.
  • Day 15: stop administration of hypericum.
Eenrichtingbord.png Start trazodone
  • Day 15-30: a wash-out period of at least two weeks is necessary.
  • Day 31: start trazodone 100-150 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is possible without wash-out period.
  • Hypericum induces enzymes of the CYP P-450 type and P-gp.
  • Hypericum probably has MAO-inhibiting properties.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.